Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752491 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
A Phase 1 study, sponsored by Joseph J. Cullen, MD, FACS.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01752491 is a Phase 1 study that has completed, run by Joseph J. Cullen, MD, FACS. The registered enrollment target is 13 participants.
The verdict
NCT01752491, a Phase 1 study, has completed, sponsored by Joseph J. Cullen, MD, FACS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma multiforme (GBM).
Interventions
- DRUG Temozolomide
- RADIATION Radiation therapy
- DRUG Ascorbate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01752491
The ClinicalTrials.gov registry entry for NCT01752491 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph J. Cullen, MD, FACS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT01752491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01752491 about?
NCT01752491 is a clinical study titled "A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme". This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for initial treatment of glioblastoma multiforme (GBM).
What is the current status of trial NCT01752491?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-04-01. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT01752491?
The interventions under investigation include: Temozolomide (DRUG), Radiation therapy (RADIATION), Ascorbate (DRUG).
Who is sponsoring clinical trial NCT01752491?
This trial is sponsored by Joseph J. Cullen, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.